Pharmacological inhibition of EZH2 by GSK126 decreases atherosclerosis by modulating foam cell formation and monocyte adhesion in apolipoprotein E‑deficient mice

Wei,Xianjing; Zhang,Ying; Xie,Lianna; Wang,Kaijun; Wang,Xiaoqing

doi:10.3892/etm.2021.10273

Pharmacological inhibition of EZH2 by GSK126 decreases atherosclerosis by modulating foam cell formation and monocyte adhesion in apolipoprotein E‑deficient mice

Authors:
- Xianjing Wei
- Ying Zhang
- Lianna Xie
- Kaijun Wang
- Xiaoqing Wang
View Affiliations

Affiliations: Department of Cardiology, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning 116023, P.R. China
Published online on: June 6, 2021 https://doi.org/10.3892/etm.2021.10273
Article Number: 841
Copyright: © Wei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Histone modifications play an important role in the occurrence and development of atherosclerosis in human and atherosclerosis‑prone mice. Histone methylation in macrophages, monocytes and endothelial cells markedly influence the progression of atherosclerosis. However, it remains unclear whether treatment with a histone methyltransferase enhancer of zeste homolog 2 (EZH2) inhibitor may suppress atherosclerosis. The present study aimed to determine the effects of the EZH2 inhibitor, GSK126, on the suppression and regression of atherosclerosis in apolipoprotein E‑deficient mouse models. In vitro, it was found that pharmacological inhibition of EZH2 by GSK126 markedly reduced lipid transportation and monocyte adhesion during atherogenesis, predominantly through increasing the expression levels of ATP‑binding cassette transporter A1 and suppressing vascular cell adhesion molecule 1 in human THP‑1 cells. In vivo, it was found that atherosclerotic plaques in GSK126‑treated mice were significantly decreased when comparing with the vehicle‑treated animals. These results indicated that the GSK126 has the ability to attenuate the progression of atherosclerosis by reducing macrophage foam cell formation and monocyte adhesion in cell and mouse models. In conclusion, the present study provided new insights into the molecular mechanism behind the action of GSK126 and suggested its therapeutic potential for the treatment of atherosclerosis.

View Figures

View References

1	Libby P, Ridker PM and Hansson GK: Progress and challenges in translating the biology of atherosclerosis. Nature. 473:317–325. 2011.PubMed/NCBI View Article : Google Scholar
2	Libby P: Inflammation in atherosclerosis. Nature. 420:868–874. 2002.PubMed/NCBI View Article : Google Scholar
3	Hansson GK and Libby P: The immune response in atherosclerosis: A double-edged sword. Nat Rev Immunol. 6:508–519. 2006.PubMed/NCBI View Article : Google Scholar
4	Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 352:1685–1695. 2005.PubMed/NCBI View Article : Google Scholar
5	Jonasson L, Holm J, Skalli O, Bondjers G and Hansson GK: Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis. 6:131–138. 1986.PubMed/NCBI View Article : Google Scholar
6	Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, Rosenfeld ME, Schwartz CJ, Wagner WD and Wissler RW: A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol. 15:1512–1531. 1995.PubMed/NCBI View Article : Google Scholar
7	Ross R: Atherosclerosis is an inflammatory disease. Am Heart J. 138:S419–S420. 1999.PubMed/NCBI View Article : Google Scholar
8	Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, Farb A, Guerrero LJ, Hayase M, Kutys R, et al: Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med. 349:2316–2325. 2003.PubMed/NCBI View Article : Google Scholar
9	van der Wal AC, Das PK, Bentz van de Berg D, van der Loos CM and Becker AE: Atherosclerotic lesions in humans. In situ immunophenotypic analysis suggesting an immune mediated response. Lab Invest. 61:166–170. 1989.PubMed/NCBI
10	Wang XQ, Wan HQ, Wei XJ, Zhang Y and Qu P: CLI-095 decreases atherosclerosis by modulating foam cell formation in apolipoprotein E-deficient mice. Mol Med Rep. 14:49–56. 2016.PubMed/NCBI View Article : Google Scholar
11	Opar A: Where now for new drugs for atherosclerosis? Nat Rev Drug Discov. 6:334–335. 2007.PubMed/NCBI View Article : Google Scholar
12	Wierda RJ, Geutskens SB, Jukema JW, Quax PHA and van den Elsen PJ: Epigenetics in atherosclerosis and inflammation. J Cell Mol Med. 14 (6A):1225–1240. 2010.PubMed/NCBI View Article : Google Scholar
13	Sharma P, Kumar J, Garg G, Kumar A, Patowary A, Karthikeyan G, Ramakrishnan L, Brahmachari V and Sengupta S: Detection of altered global DNA methylation in coronary artery disease patients. DNA Cell Biol. 27:357–365. 2008.PubMed/NCBI View Article : Google Scholar
14	Yi-Deng J, Tao S, Hui-Ping Z, Jian-Tuan X, Jun C, Gui-Zhong L and Shu-Ren W: Folate and ApoE DNA methylation induced by homocysteine in human monocytes. DNA Cell Biol. 26:737–744. 2007.PubMed/NCBI View Article : Google Scholar
15	Delaney C, Garg SK, Fernandes C, Hoeltzel M, Allen RH, Stabler S and Yung R: Maternal diet supplemented with methyl-donors protects against atherosclerosis in F1 ApoE(-/-) mice. PLoS One. 8(e56253)2013.PubMed/NCBI View Article : Google Scholar
16	Castro R, Rivera I, Struys EA, Jansen EE, Ravasco P, Camilo ME, Blom HJ, Jakobs C and Tavares de Almeida I: Increased homocysteine and S-adenosylhomocysteine concentrations and DNA hypomethylation in vascular disease. Clin Chem. 49:1292–1296. 2003.PubMed/NCBI View Article : Google Scholar
17	Kim M, Long TI, Arakawa K, Wang R, Yu MC and Laird PW: DNA methylation as a biomarker for cardiovascular disease risk. PLoS One. 5(e9692)2010.PubMed/NCBI View Article : Google Scholar
18	Kim J, Kim JY, Song KS, Lee YH, Seo JS, Jelinek J, Goldschmidt-Clermont PJ and Issa JP: Epigenetic changes in estrogen receptor beta gene in atherosclerotic cardiovascular tissues and in-vitro vascular senescence. Biochim Biophys Acta. 1772:72–80. 2007.PubMed/NCBI View Article : Google Scholar
19	Jiang W, Agrawal DK and Boosani CS: Cell specific histone modifications in atherosclerosis (Review). Mol Med Rep. 18:1215–1224. 2018.PubMed/NCBI View Article : Google Scholar
20	Khyzha N, Alizada A, Wilson MD and Fish JE: Epigenetics of Atherosclerosis: Emerging Mechanisms and Methods. Trends Mol Med. 23:332–347. 2017.PubMed/NCBI View Article : Google Scholar
21	Greißel A, Culmes M, Burgkart R, Zimmermann A, Eckstein HH, Zernecke A and Pelisek J: Histone acetylation and methylation significantly change with severity of atherosclerosis in human carotid plaques. Cardiovasc Pathol. 25:79–86. 2016.PubMed/NCBI View Article : Google Scholar
22	Lv YC, Tang YY, Zhang P, Wan W, Yao F, He PP, Xie W, Mo ZC, Shi JF, Wu JF, et al: Histone methyltransferase enhancer of Zeste Homolog 2-mediated ABCA1 promoter DNA methylation contributes to the progression of atherosclerosis. PLoS One. 11(e0157265)2016.PubMed/NCBI View Article : Google Scholar
23	Xu S, Xu Y, Yin M, Zhang S, Liu P, Koroleva M, Si S, Little PJ, Pelisek J and Jin ZG: Flow-dependent epigenetic regulation of IGFBP5 expression by H3K27me3 contributes to endothelial anti-inflammatory effects. Theranostics. 8:3007–3021. 2018.PubMed/NCBI View Article : Google Scholar
24	Yap TA, Winter JN, Giulino-Roth L, Longley J, Lopez J, Michot JM, Leonard JP, Ribrag V, McCabe MT, Creasy CL, et al: Phase I study of the novel enhancer of Zeste Homolog 2 (EZH2) inhibitor GSK2816126 in patients with advanced hematologic and solid tumors. Clin Cancer Res. 25:7331–7339. 2019.PubMed/NCBI View Article : Google Scholar
25	Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelson T, Heckl D, Ebert BL, Root DE, Doench JG, et al: Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 343:84–87. 2014.PubMed/NCBI View Article : Google Scholar
26	Yamauchi T, Masuda T, Canver MC, Seiler M, Semba Y, Shboul M, Al-Raqad M, Maeda M, Schoonenberg VAC, Cole MA, et al: Genome-wide CRISPR-Cas9 Screen Identifies Leukemia-Specific Dependence on a Pre-mRNA Metabolic Pathway Regulated by DCPS. Cancer Cell. 33:386–400.e5. 2018.PubMed/NCBI View Article : Google Scholar
27	Low H, Hoang A and Sviridov D: Cholesterol efflux assay. J Vis Exp. 61(e3810)2012.PubMed/NCBI View Article : Google Scholar
28	Zimetti F, Favari E, Cagliero P, Adorni MP, Ronda N, Bonardi R, Gomaraschi M, Calabresi L, Bernini F and Guardamagna O: Cholesterol trafficking-related serum lipoprotein functions in children with cholesteryl ester storage disease. Atherosclerosis. 242:443–449. 2015.PubMed/NCBI View Article : Google Scholar
29	Mestas J and Ley K: Monocyte-endothelial cell interactions in the development of atherosclerosis. Trends Cardiovasc Med. 18:228–232. 2008.PubMed/NCBI View Article : Google Scholar
30	Ley K and Huo Y: VCAM-1 is critical in atherosclerosis. J Clin Invest. 107:1209–1210. 2001.PubMed/NCBI View Article : Google Scholar
31	Iiyama K, Hajra L, Iiyama M, Li H, DiChiara M, Medoff BD and Cybulsky MI: Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ Res. 85:199–207. 1999.PubMed/NCBI View Article : Google Scholar
32	Moriwaki H, Kume N, Sawamura T, Aoyama T, Hoshikawa H, Ochi H, Nishi E, Masaki T and Kita T: Ligand specificity of LOX-1, a novel endothelial receptor for oxidized low density lipoprotein. Arterioscler Thromb Vasc Biol. 18:1541–1547. 1998.PubMed/NCBI View Article : Google Scholar
33	Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, Tanaka T, Miwa S, Katsura Y, Kita T, et al: An endothelial receptor for oxidized low-density lipoprotein. Nature. 386:73–77. 1997.PubMed/NCBI View Article : Google Scholar
34	Akhmedov A, Rozenberg I, Paneni F, Camici GG, Shi Y, Doerries C, Sledzinska A, Mocharla P, Breitenstein A, Lohmann C, et al: Endothelial overexpression of LOX-1 increases plaque formation and promotes atherosclerosis in vivo. Eur Heart J. 35:2839–2848. 2014.PubMed/NCBI View Article : Google Scholar
35	Frostegård J, Nilsson J, Haegerstrand A, Hamsten A, Wigzell H and Gidlund M: Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. Proc Natl Acad Sci USA. 87:904–908. 1990.PubMed/NCBI View Article : Google Scholar
36	Greißel A, Culmes M, Napieralski R, Wagner E, Gebhard H, Schmitt M, Zimmermann A, Eckstein HH, Zernecke A and Pelisek J: Alternation of histone and DNA methylation in human atherosclerotic carotid plaques. Thromb Haemost. 114:390–402. 2015.PubMed/NCBI View Article : Google Scholar
37	Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T, et al: EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science. 338:1465–1469. 2012.PubMed/NCBI View Article : Google Scholar
38	Liu Y, Peng J, Sun T, Li N, Zhang L, Ren J, Yuan H, Kan S, Pan Q, Li X, et al: Epithelial EZH2 serves as an epigenetic determinant in experimental colitis by inhibiting TNFα-mediated inflammation and apoptosis. Proc Natl Acad Sci USA. 114:E3796–E3805. 2017.PubMed/NCBI View Article : Google Scholar
39	Wierda RJ, Rietveld IM, van Eggermond MCJA, Belien JAM, van Zwet EW, Lindeman JHN and van den Elsen PJ: Global histone H3 lysine 27 triple methylation levels are reduced in vessels with advanced atherosclerotic plaques. Life Sci. 129:3–9. 2015.PubMed/NCBI View Article : Google Scholar
40	Zhang X, Wang Y, Yuan J, Li N, Pei S, Xu J, Luo X, Mao C, Liu J, Yu T, et al: Macrophage/microglial Ezh2 facilitates autoimmune inflammation through inhibition of Socs3. J Exp Med. 215:1365–1382. 2018.PubMed/NCBI View Article : Google Scholar
41	Villanueva MT: Anticancer drugs: All roads lead to EZH2 inhibition. Nat Rev Drug Discov. 16(239)2017.PubMed/NCBI View Article : Google Scholar
42	Kim KH and Roberts CWM: Targeting EZH2 in cancer. Nat Med. 22:128–134. 2016.PubMed/NCBI View Article : Google Scholar
43	McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A III, Diaz E, et al: EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 492:108–112. 2012.PubMed/NCBI View Article : Google Scholar
44	Kaniskan HÜ and Jin J: Chemical probes of histone lysine methyltransferases. ACS Chem Biol. 10:40–50. 2015.PubMed/NCBI View Article : Google Scholar
45	Zhou J, Huang S, Wang Z, Huang J, Xu L, Tang X, Wan YY, Li QJ, Symonds ALJ, Long H, et al: Targeting EZH2 histone methyltransferase activity alleviates experimental intestinal inflammation. Nat Commun. 10(2427)2019.PubMed/NCBI View Article : Google Scholar